乳腺癌新辅助化疗  

Neoadjuvant of Breast Cancer

作　　者：杨越[1] 刘跃英[1] 

机构地区：[1]昆明医学院第一附属医院普外科,昆明650032

出　　处：《昆明医学院学报》2003年第1期108-111,共4页Journal of Kunming Medical College

摘　　要：目前对于可切除的乳腺癌的治疗策略有了较大的进展 ,大量的临床和实验室研究发现 ,乳腺癌在“早期”就可能发生远处播散 ,乳腺癌手术范围的大小并无影响病人的长期生存率 ,而辅助性的全身化疗却可以显著地提高乳腺癌患者的无瘤生存率和总体生存率 .近 4 0a来 ,由于手术治疗联合术后辅助性化疗的广泛应用 ,使乳腺癌的治疗效果得到了明显的提高 .由于术前辅助化疗本质属于辅助化疗 ,而其可能的作用机制又不同于一般的术后辅助化疗 。Therapeutic strategy of operable breast cancer has made great progress. Through a great deal research in clinic and lab, there is no evidence that breast cancer has metastasis in early stage. Operative range does not work on a long term of viability. Contrarily, neoadjuvant chemotherapy evidently increased non-tumor viability and total viability. Recent 40 years, widely applicative operation combined with general chemotherapy for breast cancer has markedly improved curative effect. Preoperative chemotherapy is part of adjuvant chemotherapy, but mechanisms of the action are different from those of general chemotherapy. Therefore, it is called neoadjuvant chemotherapy.

关 键 词：乳腺癌 新辅助化疗 疗效 方法 

分 类 号：R737.9[医药卫生—肿瘤]